There was no significant difference in the proportion of individuals who received iron at least once during the study . Among individuals who received a scholarly research drug, one or more blood transfusions were performed in 123 patients in the darbepoetin alfa group and in 188 in the placebo group . Study Outcomes The primary composite outcome of death from any cause or first hospitalization for worsening heart failure occurred in 576 patients in the darbepoetin alfa group and 565 in the placebo group . The result of the evaluation adjusted for baseline features was comparable , while was the consequence of the as-treated evaluation .The original intent of the costs was that it be abortion-neutral, NPR reports. The response appears to be no . This article is republished with kind permission from our close friends at The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Survey, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Daily Health Plan Report is released for Kaisernetwork.org, a free assistance of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Panel Kaiser and Company Family Foundation. All rights reserved. Nab-P is an injectable formulation of paclitaxel that has a better therapeutic index than standard solvent-based paclitaxel and offers been proven in preclinical models to deliver a 33 percent higher medication focus to tumors.